Tadalafil Tablet, Film Coated
Product Images NDC 68071-5202

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-5202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5202 3)

The text appears to be a product label for Tadalafil from NuCare Pharmaceuticals, Inc. It includes information such as the lot number, serial number, and expiration date, as well as instructions on storage and a warning to keep the product out of reach from children.*

FDA Label Image

Figure (Tadalafil Figure1)

This appears to be a table showing the difference in blood pressure in mmHg between Tadalafil and Placebo for standing and supine positions. It also shows the time in hours.*

FDA Label Image

Figure (Tadalafil Figure2)

This text seems to represent tabular data with some numbers and symbols, including some currency symbols, letters, and some other characters that could not be recognized by . Without context or further information, it is not possible to provide a meaningful description or interpretation of the text.*

FDA Label Image

Figure (Tadalafil Figure3)

The text includes a chart with information about the impact of taking tadalafil and doxazosin on systolic blood pressure at different times after administration. No further information is available.*

FDA Label Image

Figure (Tadalafil Figure4)

This is a graph showing Plasma Tadalafil Concentration (ug/L) at different times (in hours) after the administration of tadalafil in different doses (single 20-mg dose, single 5-mg dose, and once daily 5-mg dose for 5 consecutive days). The concentration is plotted on the y-axis, and time is plotted on the x-axis. The graph indicates that tadalafil concentration increases rapidly after administration and reaches a peak concentration in the blood within a few hours, and then gradually decreases over time.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

The text provides information about the change in IPSS (International Prostate Symptom Score) total score during treatment with tadalafils and placebo. The graph shows that tadalafils mg resulted in a statistically significant improvement in IPSS total score compared to placebo (p<0.01) over the 12 weeks of treatment.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

FDA Label Image

Figure 7 (Tadalafil Figure7)

FDA Label Image

Figure 8 (Tadalafil Figure8)

FDA Label Image

Chemical Structure (Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.